RxDoctor Payments Data

April Oxford, MD

Internal Medicine · Clermont, FLNPI 1003108325

Payments from drug & device makers

$7,116in general payments, 2019–2025

Across 373 payments — averaging $19.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$1K
  • AbbVie$1K
  • Pfizer$689
  • Lilly USA, LLC$478
  • Astellas Pharma US Inc$389
  • plus $2K from 31 others

What the payments were for

  • Food & beverage$7,116100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,116 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$64,086
Medicare patients
207
Services billed
644

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide55$63,448
RybelsusSemaglutide20$54,956
EliquisApixaban39$51,895
OzempicSemaglutide33$34,476
FarxigaDapagliflozin Propanediol33$32,002
JardianceEmpagliflozin27$30,445
TrulicityDulaglutide15$21,126
XareltoRivaroxaban22$20,932
BrilintaTicagrelor14$7,772
SynthroidLevothyroxine Sodium69$5,891
Lantus SolostarInsulin Glargine,hum.Rec.Anlog42$4,304
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$4,125
Rosuvastatin Calcium202$3,162
Levothyroxine Sodium233$2,554
Advair DiskusFluticasone Propion/Salmeterol15$2,420

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$1,185$89,43253 claims
Lilly USA, LLCMounjaro, Trulicity$478$84,57470 claims
PfizerEliquis$689$51,89539 claims
AstraZenecaFarxiga, Brilinta$1,041$39,77447 claims
AbbVieSynthroid$1,019$5,89169 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$23$2,554233 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Clermont

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →